GlobeNewswire Clinical StudiesOriginal article
Serenity Medical’s River Stent™ Demonstrates Sustained 4- to 5-Year Benefits in Patients with Idiopathic Intracranial Hypertension (IIH), Presented at SNIS Annual Meeting in Late-Breaking Session
ConferencepositiveRiver Stent™Positive
AI Analysis
Summary
Serenity Medical presented long-term data on its River Stent™ at the SNIS Annual Meeting, demonstrating sustained 4- to 5-year benefits in patients with idiopathic intracranial hypertension. The data reinforce the durability of venous sinus stenting as an FDA-approved treatment option.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
River Stent™ demonstrated sustained 4- to 5-year benefits in patients with IIH; long-term data reinforce durability of venous sinus stenting
Importance:5/10
Sentiment:
0.70
venous sinus stentinglong-term dataFDA-approvedSNIS Annual Meetinglate-breaking session
Read the original article
Published by GlobeNewswire Clinical Studies on July 22, 2026 7:10 PM